Inhibition of Oxidative Stress-Elicited AKT Activation Facilitates PPARγ Agonist-Mediated Inhibition of Stem Cell Character and Tumor Growth of Liver Cancer Cells

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Liu, Lanlan ^a,b   Yang, Zhaojuan ^a   Xu, Yingqian ^a   Li, Jingyi ^a   Xu, Dongxu ^a   Zhang, Li ^a   Sun, Jiabin ^a   Xia, Suhua ^a   Zou, Feiyan ^b   Liu, Yongzhong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; ROSIGLITAZONE; SMALL INTERFERING RNA; TRICIRIBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL SURVIVAL; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; OXIDATIVE STRESS; TUMOR GROWTH; UPREGULATION;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; GLYCOPROTEINS; HUMANS; LIVER NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; NADPH OXIDASE; NEOPLASTIC STEM CELLS; OXIDATIVE STRESS; PEPTIDES; PHENOTYPE; PPAR GAMMA; PROSTAGLANDIN D2; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; RIBONUCLEOSIDES; THIAZOLIDINEDIONES;

EID: 84883313321     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073038     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Tung-Ping Poon R, Fan ST, Wong J, (2000) Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg 232: 10-24.
3. Ding W, Mouzaki M, You H, Laird JC, Mato J, et al. (2009) CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Hepatology 49: 1277-1286.
4. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, et al. (2011) CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 9: 50-63.
5. Ma S, Chan KW, Hu L, Lee TK, Wo JY, et al. (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556.
6. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, et al. (2010) miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 7: 694-707.
7. Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, et al. (2012) CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 55: 807-820.
8. Yang W, Wang C, Lin Y, Liu Q, Yu LX, et al. (2012) OV6(+) tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. J Hepatol 57: 613-620.
9. Yin S, Li J, Hu C, Chen X, Yao M, et al. (2007) CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450.
10. Sell S, Leffert HL, (2008) Liver cancer stem cells. J Clin Oncol 26: 2800-2805.
11. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
12. Yau T, Chan P, Ng KK, Chok SH, Cheung TT, et al. (2009) Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 115: 428-436.
13. Robbins GT, Nie D, (2012) PPAR gamma, bioactive lipids, and cancer progression. Front Biosci 17: 1816-1834.
14. Zhang F, Lu Y, Zheng S, (2012) Peroxisome proliferator-activated receptor-gamma cross-regulation of signaling events implicated in liver fibrogenesis. Cell Signal 24: 596-605.
15. Charytonowicz E, Terry M, Coakley K, Telis L, Remotti F, et al. (2012) PPARgamma agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma. J Clin Invest 122: 886-898.
16. Choudhary R, Li H, Winn RA, Sorenson AL, Weiser-Evans MC, et al. (2010) Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail. Neoplasia 12: 224-234.
17. Maniati E, Bossard M, Cook N, Candido JB, Emami-Shahri N, et al. (2011) Crosstalk between the canonical NF-kappaB and Notch signaling pathways inhibits Ppargamma expression and promotes pancreatic cancer progression in mice. J Clin Invest 121: 4685-4699.
18. Michalik L, Desvergne B, Wahli W, (2004) Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4: 61-70.
19. Min KW, Zhang X, Imchen T, Baek SJ, (2012) A peroxisome proliferator-activated receptor ligand MCC-555 imparts anti-proliferative response in pancreatic cancer cells by PPARgamma-independent up-regulation of KLF4. Toxicol Appl Pharmacol 263: 225-232.
20. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, et al. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4: 1046-1052.
21. Cerbone A, Toaldo C, Minelli R, Ciamporcero E, Pizzimenti S, et al. (2012) Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cells. PLoS One 7: e40149.
22. Lyles BE, Akinyeke TO, Moss PE, Stewart LV, (2009) Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell Cycle 8: 268-277.
23. Shen B, Chu ES, Zhao G, Man K, Wu CW, et al. (2012) PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Br J Cancer 106: 1486-1494.
24. Yu J, Shen B, Chu ES, Teoh N, Cheung KF, et al. (2010) Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology 51: 2008-2019.
25. Pestereva E, Kanakasabai S, Bright JJ, (2012) PPARgamma agonists regulate the expression of stemness and differentiation genes in brain tumour stem cells. Br J Cancer 106: 1702-1712.
26. Dong RC. (1989) Establishment of a human hepatocarcinoma cell line SMMC-7721 and in itial observations on its biologic characteristics. In: Tang ZY, Wu MC, Xia SS, editors. Primary liver cancer. Berlin: Springer. 145-153.
27. Yang Z, Zhang L, Ma A, Liu L, Li J, et al. (2011) Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. PLoS One 6: e28405.
28. Kohga K, Tatsumi T, Takehara T, Tsunematsu H, Shimizu S, et al. (2010) Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol 52: 872-879.
29. You H, Ding W, Rountree CB, (2010) Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 51: 1635-1644.
30. Person EC, Waite LL, Taylor RN, Scanlan TS, (2001) Albumin regulates induction of peroxisome proliferator-activated receptor-gamma (PPARgamma) by 15-deoxy-delta(12-14)-prostaglandin J(2) in vitro and may be an important regulator of PPARgamma function in vivo. Endocrinology 142: 551-556.
31. Prakash J, Bansal R, Post E, de Jager-Krikken A, Lub-de Hooge MN, et al. (2009) Albumin-binding and tumor vasculature determine the antitumor effect of 15-deoxy-Delta-(12,14)-prostaglandin-J(2) in vivo. Neoplasia 11: 1348-1358.
32. Bruedigam C, Eijken M, Koedam M, van de Peppel J, Drabek K, et al. (2010) A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone. Stem Cells 28: 916-927.
33. Shin SW, Seo CY, Han H, Han JY, Jeong JS, et al. (2009) 15d-PGJ2 induces apoptosis by reactive oxygen species-mediated inactivation of Akt in leukemia and colorectal cancer cells and shows in vivo antitumor activity. Clin Cancer Res 15: 5414-5425.
34. Lambeth JD, (2004) NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 4: 181-189.
35. Owusu-Ansah E, Banerjee U, (2009) Reactive oxygen species prime Drosophila haematopoietic progenitors for differentiation. Nature 461: 537-541.
36. Alexandre J, Hu Y, Lu W, Pelicano H, Huang P, (2007) Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 67: 3512-3517.
37. Visvader JE, Lindeman GJ, (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
38. Gilbertson RJ, Graham TA, (2012) Cancer: Resolving the stem-cell debate. Nature 488: 462-463.
39. Gires O, Klein CA, Baeuerle PA (2009) On the abundance of EpCAM on cancer stem cells. Nat Rev Cancer 9: 143; author reply 143.
40. Chen J, Li Y, Yu TS, McKay RM, Burns DK, et al. (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488: 522-526.
41. Driessens G, Beck B, Caauwe A, Simons BD, Blanpain C, (2012) Defining the mode of tumour growth by clonal analysis. Nature 488: 527-530.
42. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, et al. (2012) Lineage Tracing Reveals Lgr5+ Stem Cell Activity in Mouse Intestinal Adenomas. Science 337: 730-735.
43. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, et al. (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458: 780-783.
44. Gao X, Zhang H, Takahashi T, Hsieh J, Liao J, et al. (2008) The Akt signaling pathway contributes to postconditioning's protection against stroke; the protection is associated with the MAPK and PKC pathways. J Neurochem 105: 943-955.
45. Chai D, Wang B, Shen L, Pu J, Zhang XK, et al. (2008) RXR agonists inhibit high-glucose-induced oxidative stress by repressing PKC activity in human endothelial cells. Free Radic Biol Med 44: 1334-1347.
46. Ozaki M, Haga S, Zhang HQ, Irani K, Suzuki S, (2003) Inhibition of hypoxia/reoxygenation-induced oxidative stress in HGF-stimulated antiapoptotic signaling: role of PI3-K and Akt kinase upon rac1. Cell Death Differ 10: 508-515.
47. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY, (2008) CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749-1758.